Avivi I, Pollack S, Gideoni O, Linn S, Blumenfeld Z
Rambam Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Fertil Steril. 1996 Oct;66(4):557-63. doi: 10.1016/s0015-0282(16)58567-7.
To evaluate the reliability of the ACTH test as a means for detection of late onset congenital adrenal hyperplasia (CAH) and discriminating it from polycystic ovary syndrome (PCOS), by repeating the test after 6 months of cyproterone acetate and ethinyl E2 treatment.
Follow-up comparison study.
Reproductive Endocrinology in an university tertiary center.
Thirty-one young women with hirsutism, oligoamenorrhea, and acne, 21 of them detected as late onset CAH, and 10 as non-late onset CAH (PCOS).
Cyproterone acetate and ethinyl E2 treatment for > or = 6 months. The ACTH test, before and after 6 months of cyproterone acetate + ethinyl E2 treatment, and human leukocyte antigen (HLA) typing.
The ACTH test interpretation correlated to HLA typing.
By repeating the ACTH stimulation test in the 31 women (after cyproterone acetate + ethinyl E2 administration), we found a diminution in the rate of accumulation of 17 alpha-hydroxyprogesterone (delta 17-OHP) + P, in all 21-hydroxylase late onset CAH cases. As a result of treatment with cyproterone acetate + ethinyl E2, a decrease in the accumulation rate of 17-OHP + P, below the discriminative value for late onset CAH (6.5 ng/dL per minute), was noted among 12 of 21 women defined primarily as late onset CAH. Among the nine other women, a decrease in the accumulation rate of 17-OHP + P was noted, however not < 6.5 ng/dL per minute.
The interpretation of delta 17-OHP + P for the diagnosis of late onset CAH may be too sensitive as to the correct clinical diagnosis of late onset CAH. By repeating the ACTH test after 6 months of treatment with cyproterone acetate-ethinyl E2, specificity and accuracy may be improved.
通过在醋酸环丙孕酮和炔雌醇E2治疗6个月后重复促肾上腺皮质激素(ACTH)试验,评估ACTH试验作为检测迟发性先天性肾上腺皮质增生症(CAH)并将其与多囊卵巢综合征(PCOS)相鉴别的手段的可靠性。
随访比较研究。
一所大学三级中心的生殖内分泌科。
31名多毛、月经稀发和痤疮的年轻女性,其中21名被检测为迟发性CAH,10名被检测为非迟发性CAH(PCOS)。
醋酸环丙孕酮和炔雌醇E2治疗≥6个月。在醋酸环丙孕酮 + 炔雌醇E2治疗6个月前后进行ACTH试验,以及人类白细胞抗原(HLA)分型。
ACTH试验结果与HLA分型的相关性。
在31名女性(醋酸环丙孕酮 + 炔雌醇E2给药后)中重复进行ACTH刺激试验,我们发现所有21 - 羟化酶迟发性CAH病例中17α - 羟孕酮(δ17 - OHP)+ P的累积率降低。由于醋酸环丙孕酮 + 炔雌醇E2治疗,在最初被定义为迟发性CAH的21名女性中的12名中,17 - OHP + P的累积率下降至低于迟发性CAH的鉴别值(每分钟6.5 ng/dL)。在其他9名女性中,也观察到17 - OHP + P的累积率下降,但不低于每分钟6.5 ng/dL。
对于迟发性CAH的正确临床诊断,δ17 - OHP + P用于诊断迟发性CAH的解读可能过于敏感。通过在醋酸环丙孕酮 - 炔雌醇E2治疗6个月后重复ACTH试验,特异性和准确性可能会提高。